Previous 10 | Next 10 |
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
2023-08-11 04:21:56 ET Summary Cerus Corporation is struggling to achieve profitability and is running out of cash, likely leading to share dilution. Recent earnings report showed potential for record revenues in 2023, but the company is still facing challenges in key markets. ...
2023-08-03 10:16:24 ET Gainers: Bluejay Diagnostics ( BJDX ) +74% . Adamis Pharmaceuticals ( ADMP ) +59% . T2 Biosystems ( TTOO ) +47% . Community Health Systems ( CYH ) +18% . Cyclo Therapeutics ( CYTH ) +17% . Losers:...
2023-08-02 22:12:14 ET Cerus Corporation (CERS) Q2 2023 Earnings Conference Call August 2, 2023 04:30 PM ET Company Participants Jessica Hanover - Vice President-Corporate Affairs Obi Greenman - president and Chief Executive Officer Vivek Jayaraman - Chief Operat...
2023-08-02 16:06:48 ET Cerus press release ( NASDAQ: CERS ): Q2 GAAP EPS of -$0.07 misses by $0.01 . Revenue of $47.7M (+0.1% Y/Y) beats by $5.92M . Adjusting full-year 2023 annual product revenue guidance to the range of $160 million to $165 million from the p...
Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2023. Recent highlights include: Second quarter 2023 total revenue of $47.7 million was comprised of total product revenue of $38.9 million and government contract revenue of $8.9 mi...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will disc...
Symposium and Abstracts Highlight Data from Studies of INTERCEPT Platelets and Plasma as well as Developmental Programs Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33 rd Regional International Society of Blood Transfusion (IS...
Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply...
2023-06-05 12:18:29 ET Cerus ( NASDAQ: CERS ) said on Monday that it has been awarded an additional $8.7M contract amendment to a $9.1M contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment ( IBAS ) program. Source: Press Release ...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...